杜氏肌营养不良患者的呼吸管理指南解读
本文为美国疾控中心资助的杜氏肌营养不良呼吸管理指南2018年更新版,强调依靠有限呼吸检测指导评估与治疗,提出肺容积招募、辅助咳嗽和辅助通气(先夜间、后日间)的渐进策略,并强调连续监测呼吸肌力以刻画严重表型及作为临床试验基线。
要点
- 呼吸管理采用渐进策略:肺容积招募、辅助咳嗽、辅助通气(先夜间后日间)。
- 连续监测呼吸肌力以刻画个体呼吸严重表型并提供临床试验基线。
- 儿科到成人呼吸照护的有效过渡对优化安全、预后和生活质量至关重要。
核心结论
- 杜氏肌营养不良呼吸管理指南2018年更新版强调依靠有限呼吸检测指导评估与管理的原则。
- 提出渐进治疗策略,包括肺容积招募、辅助咳嗽和辅助通气(初始夜间,随呼吸衰竭进展加日间)。
- 强调连续监测呼吸肌力以刻画个体呼吸严重表型并提供临床试验基线评估。
研究设计与样本
- 指南由美国疾病控制与预防中心资助制定,2010年首版发表于Lancet Neurology,2018年更新。
主要发现
- 自首版指南发布以来,杜氏肌营养不良患者生存期增加,当代医疗管理下生存常延至第四十年及以后。
关键数值与推荐
- 呼吸管理依赖有限数量的呼吸检测指导患者评估和管理。
- 渐进治疗策略包括肺容积招募、辅助咳嗽和辅助通气(初始夜间,随后加日间通气)。
- 连续监测呼吸肌力以刻画个体呼吸严重表型并提供临床试验基线评估。
临床怎么用
- 临床应依据有限呼吸检测进行杜氏肌营养不良患者的评估和管理。
- 按渐进策略实施肺容积招募、辅助咳嗽和辅助通气(先夜间后日间)。
- 连续监测呼吸肌力以评估严重程度并作为临床试验基线。
- 重视儿科到成人呼吸照护的有效过渡以优化安全、预后和生活质量。
局限性
- 原文未报告具体研究设计、样本量、数值、P值等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2010, Care Considerations for Duchenne Muscular Dystrophy, sponsored by the Centers for Disease Control and Prevention, was published in Lancet Neurology, and in 2018, these guidelines were updated. Since the publication of the first set of guidelines, survival of individuals with Duchenne muscular dystrophy has increased. With contemporary medical management, survival often extends into the fourth decade of life and beyond. Effective transition of respiratory care from pediatric to adult medicine is vital to optimize patient safety, prognosis, and quality of life. With genetic and other emerging drug therapies in development, standardization of care is necessary to accurately assess treatment effects in clinical trials. This revision of respiratory recommendations preserves a fundamental strength of the original guidelines: namely, reliance on a limited number of respiratory tests to guide patient assessment and management. A progressive therapeutic strategy is presented that includes lung volume recruitment, assisted coughing, and assisted ventilation (initially nocturnally, with the subsequent addition of daytime ventilation for progressive respiratory failure). This revision also stresses the need for serial monitoring of respiratory muscle strength to characterize an individual's respiratory phenotype of severity as well as provide baseline assessments for clinical trials. Clinical controversies and emerging areas are included.
引用
- Sheehan DW, Birnkrant DJ, Benditt JO, et al. Respiratory Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018. PMID: 30275250. doi:10.1542/peds.2018-0333H
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。